Review ArticleClinical Review

Brief Intervention for Anxiety in Primary Care Patients

Peter Roy-Byrne, Jason P. Veitengruber, Alexander Bystritsky, Mark J. Edlund, Greer Sullivan, Michelle G. Craske, Stacy Shaw Welch, Raphael Rose and Murray B. Stein
The Journal of the American Board of Family Medicine March 2009, 22 (2) 175-186; DOI: https://doi.org/10.3122/jabfm.2009.02.080078

References

  1. ↵
    Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 617–27.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Twelve-month use of mental health services in the United States. Results from the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 629–40.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Stein MB, Roy-Byrne PP, Craske MG, et al. Functional impact and health utility of anxiety disorders in primary care outpatients. Med Care 2005; 43: 1164–70.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Katon W, Roy-Byrne P, Russo J, Cowley D. Cost-effectiveness and cost offset of a collaborative care intervention for primary care patients with panic disorder. Arch Gen Psychiatry 2002; 59: 1098–104.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    Stein MB, Sherbourne CD, Craske MG, et al. Quality of care for primary care patients with anxiety disorders. Am J Psychiatry 2004; 161: 2230–7.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Nisenson LG, Pepper CM, Schwenk TL, Coyne JC. The nature and prevalence of anxiety disorders in primary care. Gen Hosp Psychiatry 1998; 20: 21–8.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    Ormel J, Koeter MW, van den Brink W, van de Willige G. Recognition, management, and course of anxiety and depression in general practice. Arch Gen Psychiatry 1991; 48: 700–6.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Kroenke K, Jackson JL, Chamberlin J. Depressive and anxiety disorders in patients presenting with physical complaints: clinical predictors and outcome. Am J Med 1997; 103: 339–47.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    Mojtabai R, Olfson M, Mechanic D. Perceived need and help-seeking in adults with mood, anxiety, or substance use disorders. Arch Gen Psychiatry 2002; 59: 77–84.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    Stein MB, McQuaid JR, Pedrelli P, Lenox R, McCahill ME. Posttraumatic stress disorder in the primary care medical setting. Gen Hosp Psychiatry 2000; 22: 261–9.
    OpenUrlCrossRefPubMedWeb of Science
  11. Leon AC, Olfson M, Broadhead WE, et al. Prevalence of mental disorders in primary care: implications for screening. Arch Fam Med 1995; 4: 857–61.
    OpenUrlCrossRefPubMed
  12. Sherbourne CD, Jackson CA, Meredith LS, Camp P, Wells KB. Prevalence of comorbid anxiety diorders in primary care outpatients. Arch Fam Med 1996; 5: 27–34.
    OpenUrlCrossRefPubMedWeb of Science
  13. Spitzer RL, Kroenke K, Williams JBW. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999; 282: 1737–44.
    OpenUrlCrossRefPubMedWeb of Science
  14. Kroenke K, Spitzer RL, Williams JB, et al. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med 2007; 146: 317–25.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    Sullivan G, Craske MG, Sherbourne C, et al. Design of the Coordinated Anxiety Learning and Management (CALM) study: innovations in collaborative care for anxiety disorders. Gen Hosp Psychiatry 2007; 29: 379–87.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    Miller WR, Rollnick S. Motivational interviewing: preparing people to change addictive behavior. New York: Guilford Press; 1991.
  17. ↵
    Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract 2004; 17: 59–67.
    OpenUrlCrossRefPubMed
  18. ↵
    Means-Christensen A, Sherbourne CD, Roy-Byrne PP, Craske MG, Stein MB. Using five questions to screen for five common mental disorders in primary care: the anxiety and depression detector (ADD). Gen Hosp Psychiatry 2006; 28: 108–18.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    U.S. PSTF: Screening for Depression
  20. ↵
    Whooley MA, Avins AL, Miranda J, Browner WS. Case-finding instruments for depression. Two questions are as good as many. J Gen Intern Med 1997; 12: 439–45.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res 2007; 31: 1208–17.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    Butt Z, Wagner LI, Beaumont JL, et al. Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice. J Pain Symptom Manage 2008; 35: 20–30.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    Sareen J, Cox BJ, Afifi TO, et al. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry 2005; 62: 1249–57.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    Linehan MM, Goodstein JL, Nielsen SL, Chiles JA. Reasons for staying alive when you are thinking of killing yourself: the reasons for living inventory. J Consult Clin Psychol 1983; 51: 276–86.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    Simon NM, Otto MW, Wisniewski SR, et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2004; 161: 2222–9.
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry 2000; 157: 1873–5.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    Phelps JR, Ghaemi SN. Improving the diagnosis of bipolar disorder: predictive value of screening tests. J Affect Disord 2006; 92: 141–8.
    OpenUrlCrossRefPubMed
  28. ↵
    Lowe B, Decker O, Muller S, et al. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med Care 2008; 46: 266–74.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166: 1092–7.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    Campbell-Sills L, Norman SB, Craske MG, et al. Validation of a brief measure of anxiety-related severity and impairment: the Overall Anxiety Severity and Impairment Scale (OASIS). J Affect Disord 2008; 112: 92–101.
    OpenUrlPubMed
  31. ↵
    Norman SB, Cissell SH, Means-Christensen AJ, et al. Development and validation of an Overall Anxiety Severity And Impairment Scale (OASIS). Depress Anxiety 2006; 23: 245–9.
    OpenUrlPubMed
  32. ↵
    Katon W, Von Korff M, Lin E, Simon G. Rethinking practitioner roles in chronic illness: the specialist, primary care physician, and the practice nurse. Gen Hosp Psychiatry 2001; 23: 138–44.
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28–40.
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 2001; 62(suppl 16): 5–9.
    OpenUrl
  35. ↵
    Williams SL, Kinney PJ, Falbo J. Generalization of therapeutic changes in agoraphobia: the role of perceived self-efficacy. J Consult Clin Psychol 1989; 57: 436–42.
    OpenUrlCrossRefPubMedWeb of Science
  36. Safren SA, Heimberg RG, Juster HR. Clients’ expectancies and their relationship to pretreatment symptomatology and outcome of cognitive-behavioral group treatment for social phobia. J Consult Clin Psychol 1997; 65: 694–8.
    OpenUrlCrossRefPubMedWeb of Science
  37. Grilo CM, Money R, Barlow DH, et al. Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorder. Compr Psychiatry 1998; 39: 323–32.
    OpenUrlCrossRefPubMedWeb of Science
  38. Shear MK. Psychotherapeutic issues in long-term treatment of anxiety disorder patients. Psychiatr Clin North Am 1995; 18: 885–94.
    OpenUrlPubMed
  39. ↵
    Miller WR. Motivational interviewing: research, practice, and puzzles. Addict Behav 1996; 21: 835–42.
    OpenUrlCrossRefPubMedWeb of Science
  40. Miller WR, Baca C, Compton WM, et al. Addressing substance abuse in health care settings. Alcohol Clin Exp Res 2006; 30: 292–302.
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    Miller WR, Rollnick S. Motivational interviewing: Preparing people for change. 2nd edition. New York: Guilford Press; 2002.
  42. ↵
    Westra H, Dozois D. Preparing clients for cognitive behavior theray: a randomized pilot study of motivational interviewing for anxiety. Cognit Ther Res 2006; 30: 481–98.
    OpenUrlCrossRefWeb of Science
  43. ↵
    Slagla D, Gray M. The utility of motivational interviewing as an adjunct to exposure therapy i the treatment of anxiety disorders. Prof Psychol Res Pr 2007; 38: 329–37.
    OpenUrlCrossRef
  44. ↵
    Barlow DH. Anxiety and its disorders: the nature and treatment of anxiety and panic. New York: Guilford Press; 2002.
  45. ↵
    Swinson RP, Soulios C, Cox BJ, Kuch K. Brief treatment of emergency room patients with panic attacks. Am J Psychiatry 1992; 149: 944–6.
    OpenUrlPubMedWeb of Science
  46. ↵
    Craske MG. Anxiety disorders: psychological approaches to theory and treatment. Boulder (CO): Westview Press; 1999.
  47. ↵
    Beck A, Emery G, Greenberg R. Anxiety disorders and phobias: a cognitive perspective. New York: Basic Books; 1985.
  48. ↵
    Ost L, Westling B. Applied relaxation vs cognitive therapy in the treatment of panic disorder. Behav Res Ther 1995; 33: 145–8.
    OpenUrlCrossRefPubMedWeb of Science
  49. ↵
    Garssen B, Ruiter CD, Dyck RV, et al. Will hyperventilation syndrome survive: a responder to Ley. Clinical Psychology Review 1993; 13: 683–90.
    OpenUrl
  50. ↵
    Broman-Fulks JJ, Storey KM. Evaluation of a brief aerobic exercise intervention for high anxiety sensitivity. Anxiety Stress Coping 2008; 21: 117–28.
    OpenUrlCrossRefPubMedWeb of Science
  51. ↵
    Strohle A, Feller C, Onken M, Godemann F, Heinz A, Dimeo F. The acute antipanic activity of aerobic exercise. Am J Psychiatry 2005; 162: 2376–8.
    OpenUrlCrossRefPubMedWeb of Science
  52. ↵
    Roy-Byrne PP, Cowley D. Pharamcologic treatments for panic disorder, generalized anxiety disorders, specific phobia and social anxiety disorders. In: Nathan P, Gorman J, eds. A guide to treatments that work, 3rd edition. New York: Oxford University Press; 2007.
  53. ↵
    Stein MB. Anxiety disorders: somatic treatment. In: Sadock BJ, Sadock VA, eds. Comprehensive textbook of psychiatry, 8th edition. Baltimore (MD): Lippincott Williams & Wilkins; 2004.
  54. ↵
    Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 2001; 286: 2947–55.
    OpenUrlCrossRefPubMedWeb of Science
  55. ↵
    Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord 2000; 59: 119–26.
    OpenUrlCrossRefPubMedWeb of Science
  56. ↵
    Roy-Byrne P, Russo J, Dugdale DC, Lessler D, Cowley D, Katon W. Undertreatment of panic disorder in primary care: role of patient and physician characteristics. J Am Board Fam Pract 2002; 15: 443–50.
    OpenUrlPubMed
  57. ↵
    Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D. Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001; 58: 681–6.
    OpenUrlCrossRefPubMedWeb of Science
  58. ↵
    Rickels K, Schweizer E, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry 1990; 47: 899–907.
    OpenUrlCrossRefPubMedWeb of Science
  59. Rickels K, Schweizer E, Csanalosi I, Case WG, Chung H. Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 1988; 45: 444–50.
    OpenUrlCrossRefPubMedWeb of Science
  60. Rickels K, Schweizer E, Weiss S, Zavodnick S. Maintenance drug treatment for panic disorder. II. Short- and long-term outcome after drug taper. Arch Gen Psychiatry 1993; 50: 61–8.
    OpenUrlCrossRefPubMedWeb of Science
  61. ↵
    Pollack MH, Otto MW, Roy-Byrne PP, et al. Novel treatment approaches for refractory anxiety disorders. Depress Anxiety 2008; 25: 467–76.
    OpenUrlPubMed
  62. ↵
    Bystritsky A. Treatment-resistant anxiety disorders. Mol Psychiatry 2006; 11: 805–14.
    OpenUrlCrossRefPubMedWeb of Science
  63. ↵
    Mellman TA, Clark RE, Peacock WJ. Prescribing patterns for patients with posttraumatic stress disorder. Psychiatr Serv 2003; 54: 1618–21.
    OpenUrlCrossRefPubMedWeb of Science
  64. ↵
    Stewart SA. The effects of benzodiazepines on cognition. J Clin Psychiatry 2005; 66(suppl 2): 9–13.
    OpenUrl
  65. ↵
    Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000; 20: 467–71.
    OpenUrlCrossRefPubMedWeb of Science
  66. ↵
    Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999; 19: 341–8.
    OpenUrlCrossRefPubMedWeb of Science
  67. ↵
    Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23: 240–9.
    OpenUrlCrossRefPubMedWeb of Science
  68. ↵
    Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006; 163: 1161–72.
    OpenUrlCrossRefPubMedWeb of Science
  69. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006; 163: 1531–41; quiz 1666.
    OpenUrlCrossRefPubMedWeb of Science
  70. Rush AJ. STAR*D: what have we learned? Am J Psychiatry 2007; 164: 201–4.
    OpenUrlCrossRefPubMedWeb of Science
  71. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905–17.
    OpenUrlCrossRefPubMedWeb of Science
  72. ↵
    Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 2002; 159: 1777–9.
    OpenUrlCrossRefPubMedWeb of Science
  73. Pollack MH, Simon NM, Zalta AK, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry 2006; 59: 211–5.
    OpenUrlCrossRefPubMedWeb of Science
  74. Rothbaum BO, Killeen TK, Davidson JR, Brady KT, Connor KM, Heekin MH. Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. J Clin Psychiatry 2008; 69: 520–5.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section